Pasithea therapeutics to present new preclinical data showing pas-004 strongly inhibits nras cancer cell lines and demonstrates superior activity in xenograft studies at 2024 asco annual meeting

Pasithea to present preclinical data at asco 2024 showing pas-004 superior inhibition of nras cancer cells and xenograft tumors compared to current meki's

KTTA Ratings Summary

KTTA Quant Ranking